Figure 3
From: Vascular memory: can we broaden the concept of the metabolic memory?
Kaplan-Meier estimates illustrating the primary outcome (death from coronary artery disease [%]) in the LIPID trial. In the double blind phase of the trial (mean duration: 6.0 years) a clear difference between pravastatin and placebo occurred which was maintained in the open, post-trial observational follow-up period (duration: 2.0 years) (From Lancet 2002; 359: 1379–1387, with permission).